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Abstract
Background: Conventional methods for susceptibility testing require several months before
results can be reported. However, rapid methods to determine drug susceptibility have been
developed recently. Phage assay have been reported as a rapid useful tools for antimicrobial
susceptibility testing. The aim of this study was to apply the Phage assay for rapid detection of
resistance on Mycobacterium tuberculosis strains in Cuba.
Methods: Phage D29 assay was performed on 102 M. tuberculosis strains to detect rifampicin
resistance. The results were compared with the proportion method (gold standard) to evaluate the
sensitivity and specificity of Phage assay.
Results: Phage assay results were available in 2 days whereas Proportion Methods results were
obtain in 42 days. A total of 44 strains were detected as rifampicin resistant by both methods.
However, one strains deemed resistant by Proportion Methods was susceptible by Phage assay.
The sensitivity and specificity of Phage assay were 97.8 % and 100% respectively.
Conclusion: Phage assay provides rapid and reliable results for susceptibility testing; it's easy to
perform, requires no specialized equipment and is applicable to drug susceptibility testing in low
income countries where tuberculosis is a major public health problem.
Background
Tuberculosis (TB) remains a major cause of morbidity and
mortality worldwide. It is estimated that about one-third
of the world's population is infected with Mycobacterium
tuberculosis, more than eight million new cases of active TB
occur annually and the estimated global annual mortality
from this disease is close to two million people [1]. Multi-
drug-resistant tuberculosis (MDR-TB), caused by strains
resistant to at least isoniazid (INH) and rifampicin
(RMP), is considered an emergent disease as well as the
consequence of inadequate treatment [2]. WHO has esti-
mated that approximately 460.000 MDR-TB cases occur
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each year [3]. Estimated prevalence of MDR-TB ranges
from 0% in some western countries to 14.2% in Kaza-
khstan and Israel, high prevalence has also been observed
in the Russian Federation (Tomsk Oblast, 13.7%);
Uzbekistan (Karakalpakstan, 13.2%), Estonia (12.2%),
China (Liaoning Province, 10.4% and Henan Province,
7.8%), Lithuania (9.4%), Latvia (9.3%), and Ecuador
(6.6%) [4].
Currently available techniques for susceptibility testing
are culture based, and include the proportion method
(PM), resistance ratio and absolute concentration
method. Conventional methods require several months
before results can be reported. Delays in reporting results
lead to prolong an inadequate treatment and may sustain
transmission of drug resistant disease. More rapid detec-
tion may be obtained by using dyes to indicate bacterial
growth such as MTT and Resazurin and a number of
assays are currently being evaluated [5]. These methods
show high sensitivity and specificity values to detect
MDR-TB at lower cost than more conventional
approaches [1].
Rapid molecular methods have been developed recently,
some of which are commercially available [5]. Based on
PCR followed by reverse hybridization to identify either
specific mutations or wild-type sequences the INNO-LiPA
Rif TB assay (Innogenetics, Ghent, Belgium) detects resist-
ance to rifampicin [6], while the GenoType® MTBDR test
(Hain Lifescience Gmbh, Germany) detects resistance to
both rifampicin and isoniazid within one working day
[7]. However, their expense and the requirement for spe-
cialist skills and equipment have prevented their adoption
in countries with less favorable living conditions, where
TB is an important health problem.
Mycobacteriophages (phages) were initially investigated
as tools for investigating resistance to anti-tuberculosis
drugs over 25 years ago [8,9]. More recently mycobacteri-
ophage-based techniques have been reported for detec-
tion of viable bacilli in clinical specimens as well as for
antimicrobial susceptibility testing [10,11]. Phages are
unable to replicate in the presence of drugs such as RMP
that disrupt the mechanism of replication of the host bac-
teria. However, in drug resistant strains replication can
proceed. The resulting phage can be visualized on indica-
tor plates as clear areas (plaques) within a lawn of fast
growing mycobacteria [12]. This ingenious method,
which does not require specialist laboratory skills or
sophisticated equipment, appears to offer robust detec-
tion of RMP resistance [13]. Initial reports suggested that
resistance to rifampicin could be detected in 4 days [10],
but this has since been reduced to less than 48 hours [14].
Furthermore, the assay is available as a commercial diag-
nostic kit as well as an 'in-house' version [15].
The aim of this study was to apply the Phage assay for
rapid detection of RMP resistance on M. tuberculosis strains
in Cuba.
Methods
Strains
A total of 102 M. tuberculosis strains from the collection at
the Tuberculosis National Reference Laboratory of Insti-
tute de Medicina Tropical "Pedro Kourf" were studied in a
blinded manner. Two M. tuberculosis reference strains were
used as control of the assay, M. tuberculosis H37Rv
rifampicin sensitive (ATCC 27294) and M. tuberculosis
(ATCC 35838) rifampicin resistant. Mycobacterium smeg-
matis mc2 155 was used to produce indicator plates.
Indicator plates
Indicator plates were produced as described previously
[16]. One hundred microliters of M. smegmatis mc2 155
which was stored in Middlebrook 7H9 (Difco) at -70°C,
was spread on a plate which contained 1.5 % agar (Difco)
with Middlebrook 7H9 and 10% oleic acid albumin dex-
trose catalase (OADC; Difco). The plate was incubated for
three days at 37°C and then, one colony was taken and
placed in 300 mL of Middlebrook 7H9 with 10% OADC
and incubated for 2 days at 37°C. To prepare the plates
10% stationary phase M. smegmatis culture (100 mL) was
added in a medium which contained 15 g agar (1.5 %)
and 800 mL of Middlebrook 7H9 with 100 mL OADC (10
%). Then approximately 25 mL of this mix was poured
onto Petri dishes. Once set, the indicator plates were
stored for up to 2 weeks at 4°C.
Phage
Mycobacteriophage D29 was obtained as described previ-
ously [16]. One hundred microliters of mycobacteri-
ophage which were stored in Middlebrook 7H9 with 10%
OADC and ImM CaCl2 at 4°C were spread in an indicator
plate and incubated overnight at 37°C. Ten milliliters of
Middlebrook 7H9 with 10% OADC and ImM CaCl2 were
added and incubated overnight at 37°C. Then, the
medium was filtered through a sterile 0.45 µm filter and
stored in 0.1 mL at 4°C for as long as 6 months. The
mycobacteriophage stock was quantified by pipetting 10
µL aliquots of serial dilutions (10 fold) on an indicator
plate and the titre of plaque forming units (pfu) calcu-
lated.
Antibiotic
RMP (Sigma) was made up as stock solution at 1 mg/mL
in dimethylsulfoxide (BDH, England) and stored at -70°C
in 0.5 mL vials until use. Further dilutions were made in
Middlebrook 7H9 with 10% OADC and ImM CaCl2.Annals of Clinical Microbiology and Antimicrobials 2006, 5:11 http://www.ann-clinmicrob.com/content/5/1/11
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Phage assay
The assay was carried out as described Wilson et al. [10].
To reduce cost, the assay was performed in 0.5 mL vials.
Seventy five microliters of M. tuberculosis (McFarland No
1 turbidity) and 75 µL of RMP (20 ug/mL) were placed in
vials and incubated during 24 h at 37°C. Fifty microliters
of mycobacteriophage D29 (108 pfu/mL) were added into
the vials and it were incubated for 90 min at 37°C. Then,
the extracellular viruses were destroyed with 100 µL of
phagicidal agent ferrous ammonium sulfate at 30 mM
(Merck) [11] and finally, the mycobacteriophages were
detected by addition 10 µL of the samples on the lawn
indicator plate after overnight incubation at 37°C. A
growth control containing no drug was included for each
strain. The strains were considered resistant if lytic plaques
were observed on the indicator plate from those samples
treated with RMP; strains were considered susceptible if
no plaques were observed following drug treatment.
Proportion method
The PM was carried out on tubes with Löwenstein-Jensen
medium according to the standard procedure with the rec-
ommended critical concentration of RMP 40 mg/mL [17].
This method was used as the gold standard to evaluate the
sensitivity and specificity of Phage assay.
Results
The Phage assay and PM were performed with the purpose
to detect RMP resistance on 102 M. tuberculosis strains.
Phage assay results were available in 2 days whereas PM
results were obtained in 42 days. Table 1 shows the results
obtained by both methods. Interpretation of the results
was easy and clear. The resistant strains showed lysis on
the indicator plates in both the RPM treated and control
samples, whereas the sensitive strains had lysis only in the
growth (no drug) control (Figure 1).
Of 45 strains resistant by the PM, 44 were resistant by the
Phage assay. One strain deemed resistant by the PM was
susceptible by Phage assay. On the other hand, all the 57
susceptible strains by the PM were also classified as sus-
ceptible by Phage assay.
The overall comparison of the Phage assay with the PM
produced only one discordant result. The sensitivity of the
Phage assay in detecting RMP resistance was 97.8 %
whereas the specificity achieved was 100 %.
Discussion
Rifampicin is the most potent sterilizing drug available
and a key component for TB treatment. Since RMP resist-
ance is considered a marker of MDR in high level coun-
tries, it would be helpful for low resources countries to
have a simple and inexpensive test than can rapidly detect
resistance to RMP [5,18].
The diagnosis of MDR-TB is based on in vitro drug suscep-
tibility testing. Conventional culture-based methods are
still in routine use in most countries. Susceptibility testing
is typically performed on cultures isolated from clinical
specimens. These methods requires 3–4 weeks to obtain
the results and, combined with the time required for pri-
mary isolation, may take several months to obtain the
results. Automatic culture systems, such as Bactec 460
have reduced time to several weeks but the machine, the
tubes, and the additives are all expensive and generate
radioactive waste. Other commercial tests such as the
MGIT (mycobacterial growth indicator tube) and molecu-
lar tools such as LIPA (line probe assay) have been devel-
oped but are expensive and impractical for routine use in
resource poor settings [5].
In this study, the Phage assay was performed for rapid
detection of RMP resistance in 102 strains of M. tuberculo-
sis and the results were compared with the gold standard
PM recommended by WHO. Results of the Phage assay
were available approximately 40 days earlier than PM that
which is significant in terms of patient management [15].
One discrepant result was obtained in which the phage
test misidentified a strain as susceptible whereas PM
Interpretation of the phage assay in the indicator plates Figure 1
Interpretation of the phage assay in the indicator plates. The 
resistance strains (26 and 27) showed lysis on the indicator 
plates in both the RPM treated and control samples, whereas 
the sensitive strains (25 and 28) had lysis only in the growth 
(no drug) control.Annals of Clinical Microbiology and Antimicrobials 2006, 5:11 http://www.ann-clinmicrob.com/content/5/1/11
Page 4 of 5
(page number not for citation purposes)
determined it as resistant. When tested by the colorimetric
MTT and Resazurin Microtitre Assays [18] this strain
showed resistance to RMP >2 mg/L by both methods. The
failure of D29 to detect resistant bacilli in this sample may
be due to experimental error or could be ascribed to tech-
nical problems regarding phage replication which will not
proceed in bacilli that are dormant or where replication
has been disrupted. It is possible that the presence of
aggregates of bacteria may have deterred phage access to
the rifampicin resistant bacilli in this sample. To date, no
strains of M. tuberculosis or M. smegmatis have been identi-
fied that lack the binding site for D29 on their cell wall
[13]. When reporting results some authors have applied
proportional analysis to the numbers of plaque forming
units observed. However, most researchers, including us,
prefer criteria in which the presence of a simple plaque is
indicative of resistance [14,19,20].
The results of the present research are similar to those
obtained in Argentina and Brazil by Simboli et al. and da
Silva et al. [19,21]. Our result showed a good agreement
with PM and it confirms the excellent alternative for rapid
drug susceptibility testing in poor countries. On the other
hand, the assay not only can be applied to RMP but also
to INH, ethambutol, pyrazinamide, streptomycin, and
ciprofloxacin [22,23]. For more rapid screening of
patients it has recently been demonstrated that phages can
detect RMP resistance directly from smear positive spu-
tum samples [24]. However, further studies are required
to determine the sensitivity and reliability of this method.
Conclusion
The Phage assay doesn't require any specialized equip-
ment or reagents, only basic additional consumable
items, such as Petri dishes and pipettes are needed.
Besides this, the assay is easy to perform and does not
require training in specialist skills. Furthermore, the
results of our study indicate the potentiality of the simple
and inexpensive Phage assay for control programs in
countries with high levels of MDR-TB. The assay could be
use, with minor modifications, as a rapid screen for anti-
microbial resistance to the principal drugs against TB.
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